Ganciclovir Sodium Injection, Powder, Lyophilized, For Solution
Product Images NDC 70436-231

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Ganciclovir Sodium (NDC 70436-231). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Slate Run Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

T:\spl Documents\ganciclovir Injection-spl\chemical Structures.jpg (Chemical Structures)

T:\spl Documents\ganciclovir Injection-spl\chemical Structures.jpg (Chemical Structures)
Chemical structure diagrams of ganciclovir sodium and ganciclovir are shown side by side. Each structure includes a molecular formula and molecular weight: ganciclovir sodium (C9H12N5NaO4, MW 277.22) and ganciclovir (C9H13N5O4, MW 255.23). Both structures display their characteristic ring and hydroxyl group arrangements.*
FDA Label Image

T:\spl Documents\ganciclovir Injection-spl\figure 1 Pan Black C.jpg (Figure 1 Pan Black C)

T:\spl Documents\ganciclovir Injection-spl\figure 1 Pan Black C.jpg (Figure 1 Pan Black C)
A line graph titled "ICM 1653: Time to Progression of CMV Retinitis" showing proportion without progression on the vertical axis and time from start of maintenance therapy in days on the horizontal axis. Two lines represent progression over time for IV and Oral treatments, with both declining proportionally across approximately 150 days.*
FDA Label Image

T:\spl Documents\ganciclovir Injection-spl\figure 2 Pan Black C.jpg (Figure 2 Pan Black C)

T:\spl Documents\ganciclovir Injection-spl\figure 2 Pan Black C.jpg (Figure 2 Pan Black C)
A line graph titled 'ICM 1774: Time to Progression of CMV Retinitis' showing the proportion of patients without progression over time from start of maintenance therapy (days). The y-axis represents the proportion without progression from 0 to 1, and the x-axis represents time in days from 0 to 120. Two lines compare intravenous (IV, dashed line) and oral (solid line) administration, indicating a higher proportion without progression for IV over the time period.*
FDA Label Image

T:\spl Documents\ganciclovir Injection-spl\figure 3 Pan Black C.jpg (Figure 3 Pan Black C)

T:\spl Documents\ganciclovir Injection-spl\figure 3 Pan Black C.jpg (Figure 3 Pan Black C)
A Kaplan-Meier survival curve titled 'AVI 034: Time to Progression of CMV Retinitis' showing the proportion of patients without progression over time (days) from the start of maintenance therapy. Two lines represent different administration routes: intravenous (dashed line) and oral (solid line). The y-axis indicates the proportion without progression ranging from 0 to 1, and the x-axis shows time from 0 to 150 days.*
FDA Label Image

500 mg Vial (Image 01)

500 mg Vial (Image 01)
Ganciclovir for Injection, USP 500 mg per vial, lyophilized powder for intravenous infusion. The label indicates it contains 543 mg ganciclovir sodium equivalent to 500 mg ganciclovir. Manufactured by Hairen Poly Pharm and distributed by Slate Run Pharmaceuticals, LLC. Includes storage instructions, preparation directions, and cautionary information about its cytotoxic and carcinogenic potential.*
FDA Label Image

Novaplus Logo (Image 02)

Novaplus Logo (Image 02)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.